ELI LILLY & CO (LLY)

US5324571083 - Common Stock

550.01  -2.28 (-0.41%)

After market: 550.01 0 (0%)

ELI LILLY & CO

NYSE:LLY (9/26/2023, 7:18:04 PM)

After market: 550.01 0 (0%)

550.01

-2.28 (-0.41%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-08 2023-08-08/bmo
Earnings (Next)11-02 2023-11-02/bmo
Ins Owners10.65%
Inst Owners85.38%
Market Cap522.12B
Shares949.29M
PE70.51
Fwd PE42.84
Dividend Yield0.82%
Analysts81.82
IPO07-09 1970-07-09
Stock Screener Links
Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

LLY Daily chart

Company Profile

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 39,000 full-time employees. The company discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. Its diabetes products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, and Trulicity. Its oncology products consist of Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, and others. Its immunology products include Olumiant, Taltz, oral IL-17 inhibitors and others. Its neuroscience products include Cymbalta, Emgality, and Zyprexa. Its other therapies consist of Bamlanivimab and etesevimab, Bebtelovimab and Forteo. The company maintains special business groups for service wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. The company manufactures and distributes its products through facilities in the United States, including Puerto Rico, and other countries. Its products are sold in over 110 countries.

Company Info

ELI LILLY & CO

Lilly Corporate Ctr, Drop Code 1094, Lilly Corporate Ctr

Indianapolis INDIANA 46285

P: 13172762000.0

CEO: David A. Ricks

Employees: 39000

Website: https://www.lilly.com/

LLY News

News Image14 hours ago - ReutersUS judge overturns Eli Lilly's $176.5 million loss in Teva patent case

Drugmaker Eli Lilly convinced a federal judge in Massachusetts on Tuesday to overturn a $176.5 million jury verdict for Teva Pharmaceutical that found Lilly's migraine drug Emgality infringed three patents related to Teva's rival drug Ajovy.

News Image14 hours ago - Yahoo FinanceUS judge overturns Eli Lilly's $176.5 million loss in Teva patent case

Drugmaker Eli Lilly convinced a federal judge in Massachusetts on Tuesday to overturn a $176.5 million jury verdict for Teva Pharmaceutical that found Lilly's migraine drug Emgality infringed three patents related to Teva's rival drug Ajovy. U.S. District Judge Allison Burroughs said in a post-trial ruling that the Teva patents covering the use of antibodies to inhibit headache-causing peptides were invalid. "The Court does not reach this decision nor overturn a jury verdict lightly," Burroughs said.

News Image17 hours ago - InvestorPlaceDon’t Miss the Boom: 3 Biotech Stocks Set to Explode Higher

With their seamless blend of promise and innovation, these biotech stocks to buy offer a strategic gateway to fortify your portfolio.

News Image17 hours ago - The Motley Fool2 Magnificent Dividend Stocks to Buy Right Now

These two expensive dividend stocks are worth the price of admission.

News Image2 days ago - The Motley Fool3 Artificial Intelligence (AI) Stocks That Could Soar More Than Nvidia, According to Wall Street

None of these stocks have outperformed Nvidia so far this year. But the next 12 months could be a different story.

News Image3 days ago - The Motley Fool3 Magnificent Growth Stocks to Buy Right Now

If you're looking for growth, these stocks could be just the ticket.

LLY Twits

Here you can normally see the latest stock twits on LLY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example